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Introduction {#sec1}
============

Antibiotics are useful for treating bacterial infections. However, the worldwide emergence of drug-resistant bacteria is a great threat to antibiotic efficacy. Cyclic lipopeptides (CLPs) produced by diverse groups of bacteria are receiving more and more attention because of their broad-spectrum activity against microorganisms, including multidrug-resistant pathogens ([@bib2], [@bib20]). All CLPs are composed of a circular oligopeptide linked to a fatty acid chain. They also have a similar mode of action, which involves membrane integrity impairment and dissipation of membrane potential ([@bib20]). In recent years, studies have revealed that CLPs might have a second mode of action ([@bib2], [@bib9], [@bib22], [@bib24]). A recently identified CLP, lysocin E, was shown to inhibit respiration in *Staphylococcus aureus* by directly interacting with menaquinone ([@bib9]). The well-studied daptomycin (DAP) could cause dissipation of membrane potential and cell death without damaging membrane integrity. Moreover, polymyxin B (PB) was found to inhibit NADH dehydrogenase (NDH) from the gram-positive bacterium *M. smegmatis* ([@bib16]).

DAP and PB are two important CLPs that have been used in medical treatment for decades. Unfortunately, pathogens resistant to DAP and PB have emerged ([@bib15]). However, knowledge of the CLPs\' resistance mechanism is restricted to the modification of the cell wall, cell membrane, or outer membrane ([@bib3], [@bib6], [@bib23]). The *dlt* operon in *S. aureus* could reduce the negative charge of the cell surface and keep DAP away from the cell membrane ([@bib3]). MprF is a DAP-resistant protein responsible for lysinylation of PG, which also reduces the negative charge of the cell surface in *S. aureus* ([@bib3]). Fischer et al. compared the transcriptomic and proteomic profiles of a DAP-resistant methicillin-resistant *S. aureus* strain with those of the DAP-sensitive strain ([@bib6]). Their results showed that many genes involved in cell wall metabolism were significantly up-regulated in the DAP-resistant isolate, indicating the important role of cell wall in DAP resistance ([@bib6]). PmrA-PmrB in *Salmonella* is a two-component system that responds to the cellular iron level, induces the expression of genes involved in outer membrane modification, and confers PB resistance ([@bib23]).

Glucose is a prior carbon source that can support rapid growth of microorganisms ([@bib19]). Several recent studies showed that glucose and other carbon sources such as mannitol, fructose, and glycerol could affect the antibiotic sensitivity of the microorganism by regulating the metabolic state. Allison et al. found that these carbon sources could activate the membrane potential of *Escherichia coli* persisters, thus potentiating their sensitivity to aminoglycosides ([@bib1]). Similarly, Peng et al. showed that glucose could restore antibiotic-resistant bacterial sensitivity to antibiotics by increasing the proton motive force (PMF), which mediates the uptake of antibiotics ([@bib17]). Here, we found that glucose and some carbon sources exert an effect on bacterial resistance to CLPs and reveal a distinct mechanism underlying interaction between the metabolic state of bacteria and the bactericidal activity of antibiotics. PB caused respiratory malfunction and serious depletion of ATP, contributing to PB-induced cell death and an obvious carbon starvation response. The addition of glucose could maintain the intracellular ATP level and reverse the carbon starvation response resulting from treatment of PB. The results indicated that glucose induced bacterial resistance to PB by maintaining the intracellular ATP level in PB-treated bacteria through enhanced glycolysis. Similar results were also observed in *S. aureus*, where DAP resistance was enhanced by glucose. These findings demonstrated that the intracellular ATP level was important for the mode of action of CLPs, and they provide insight into bacterial resistance to these antibiotics.

Results {#sec2}
=======

Glucose-Induced Drug Resistance to CLPs {#sec2.1}
---------------------------------------

We previously studied the mode of action of CLPs on *B. subtilis* using transcriptome analysis, which revealed that CLPs caused significant carbon starvation ([@bib26]). We wondered if the bactericidal activity of CLPs was related to carbon metabolism. Here, we investigated the effect of some carbon sources (20 mM glucose, fructose, glycerol, and arabinose) on the bactericidal activity of PB in *B. subtilis* ([Figures 1](#fig1){ref-type="fig"}A and B). *B. subtilis* cells incubated in Luria broth medium with or without carbon sources were treated with 50 μg/mL PB. As shown in [Figures 1](#fig1){ref-type="fig"}A and 1B, both glucose and fructose significantly enhanced drug resistance to PB in *B. subtilis*. Glycerol and arabinose had weaker effect on PB resistance in *B. subtilis* ([Figure 1](#fig1){ref-type="fig"}B). To study if glucose-induced resistance is applicable to other CLPs, we tested the effect of glucose on *B. subtilis*\' resistance to DAP. As shown in [Figure 1](#fig1){ref-type="fig"}C, glucose also enhanced *B. subtilis\'* resistance to DAP. With increase in glucose concentrations, bacterial resistance to DAP increased. However, these results showed that higher concentration of glucose (15 mM) was needed to completely inhibit the activity of DAP with a concentration of 5 μg/mL ([Figure 1](#fig1){ref-type="fig"}C). This might be because the activity of DAP is more efficient than that of PB when treating *B. subtilis*. We also tested if glucose induced resistance to other cationic antimicrobial peptides (such as vancomycin \[VAN\]). However, with the presence of glucose, resistance of *B. subtilis* to VAN was not enhanced ([Figure 1](#fig1){ref-type="fig"}D).Figure 1Glucose-Induced Drug Resistance to CLPsThree biological replicates were used for each assay. Data are represented as mean ± SD.(A) Live percentage of *B. subtilis* culture after no treatment (control) and treatment of PB, glucose (Glc), and PB plus 5, 10, 15, and 20 mM Glc.(B) Live percentage of *B. subtilis* culture after no treatment and treatment of PB, Glc, PB plus Glc, fructose (Fru), PB plus Fru, arabinose (Ara), PB plus Ara, glycerol (Gly), and PB plus Gly. The pyruvate cycle increases aminoglycosides\' efficacy and provides respiratory energy in bacteria.(C) Live percentage of *B. subtilis* culture after no treatment and treatment of DAP, Glc, and DAP plus 5, 10, 15, and 20 mM Glc.(D) Live percentage of *B. subtilis* culture after no treatment, VAN, Glc, and VAN plus 5, 10, 15, and 20 mM Glc.

To investigate the relationship between carbon metabolism and the action of CLPs, proteomic analysis was performed with *B. subtilis* cells treated with PB, PB plus glucose, or glucose. After applying a cutoff value of 1.2-fold change (p \< 0.05), the expressions of 805, 594, and 478 proteins were found to be significantly changed after treatment by PB, PB plus glucose, or glucose, respectively ([Figure S1](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc2){ref-type="supplementary-material"}). As shown in the [Figure 2](#fig2){ref-type="fig"}, MalP and ManP were involved in mannose uptake, MtlA was involved in mannitol uptake, LevDE was involved in fructose uptake, GlpTK was involved in glycerol uptake, AcoL was involved in acetoin catabolism, RocG was involved in glutamate catabolism and the proteins SdhAB that compose the succinate dehydrogenase complex, AcsA was involved in acetate utilization, and GapB was involved in glucogenesis, and they were all significantly up-regulated in PB-treated *B. subtilis* ([Figure 2](#fig2){ref-type="fig"}). However, no change was observed in *B. subtilis* treated with PB plus glucose ([Figure 2](#fig2){ref-type="fig"}). Pgi, Pgk, Eno, FbaA, and Ldh were involved in the glycolysis pathway, and they were significantly down-regulated by PB treatment. None of them were down-regulated after treatment with PB plus glucose. In *B. subtilis*, alternative carbon acquisition or metabolism is repressed, whereas catabolism of glucose is activated by CcpA, which senses the energy status of the cell and is activated by fructose-1,6-bisphosphate (FBP) or high ATP concentrations ([@bib13], [@bib19]). These results might indicate that PB resulted in a lower energy status before being reverted by glucose.Figure 2Expression Levels of Proteins Involved in Carbon Metabolism and Aerobic Respiration of *B. subtilis* Treated with PB, PB Plus Glucose, or GlucoseThree columns from left to right represent expression ratios of proteins in response to treatment of PB (blue), PB plus glucose (green), and glucose (yellow). Two dotted lines were used to indicate the cutoff value: red line (1.2-fold) and green line (0.83-fold).

The proteins involved in respiration are also shown in [Figure 2](#fig2){ref-type="fig"}. PB repressed cytochrome caa3 (CtaCDF), menaquinol-cytochrome c reductase (QcrABC), and cytochrome bd (CydA) expression, but it induced NADH-Q dehydrogenase (YjlD, renamed Ndh) and succinate dehydrogenase (SdhAB) expression. It seems that PB led to respiratory malfunction. Mogi et al. reported that PB can inhibit NADH-Q dehydrogenase in *M. smegmatis* ([@bib16]). It is possible that PB could inhibit NADH-Q dehydrogenase, causing NADH/NAD^+^ and Q/QH~2~ increases that lead to Ndh induction and repression of CtaCDF, QcrABC, and CydA. In *B. subtilis*, Ndh expression is induced by an increased NADH/NAD^+^ ratio ([@bib8]), whereas CydA, QcrABC, and CtaCDF expression might be repressed due to an increased Q/QH~2~ ratio ([@bib7]). After PB plus glucose treatment, expression of QcrABC and CtaCDF was also significantly repressed. However, Ndh expression was less up-regulated, and CydA was significantly up-regulated. These observations indicated that glucose could revert the NADH/NAD^+^ increase and cause some degree of respiratory malfunction.

PB Inhibited NADH Dehydrogenase and ATP Synthesis, Leading to ATP Depletion {#sec2.2}
---------------------------------------------------------------------------

The proteomics results revealed an increase in the NADH/NAD^+^ ratio, and Mogi et al. reported that PB can inhibit NADH-Q dehydrogenase in *M. smegmatis*. We reasoned that PB might also inhibit respiratory NDH in *B. subtilis* ([@bib16]). To test this, *B. subtilis* cell membrane preparation was treated with or without PB in the presence of menaquinone and NADH. As shown in [Figure 3](#fig3){ref-type="fig"}, the decreasing velocity of NADH was much slower with PB, indicating that NDH enzyme activity was inhibited by PB ([Figure 3](#fig3){ref-type="fig"}A). The IC50 values of PB to NDH were determined to be 18.82 μg/mL. *B. subtilis* is a facultative anaerobe whose ATP was mainly supplied by aerobic respiration under aerobic conditions. Inhibition of respiratory NDH might inhibit ATP synthesis. Moreover, PB causes dissipation of PMF, which activates F0-F1 ATP synthetase ([@bib14]). This result suggested that PB might inhibit ATP synthesis *in vivo*. The intracellular ATP level in PB-treated bacteria was determined using the ATP-analyzing kit. We found that the ATP level decreased in PB-treated bacteria in a dose-dependent manner ([Figure 3](#fig3){ref-type="fig"}B). To examine if ATP depletion results in the bactericidal action of PB, *B. subtilis* was pretreated with 1 mM dicyclohexylcarbodiimide (DCCD), which is an inhibitor of F0-F1 ATP synthase. As shown in [Figures 3](#fig3){ref-type="fig"}C and 3D, *B. subtilis* pretreated with DCCD were more sensitive to PB, which is indicated by a faster OD600 drop and lower ATP level. These results indicated that PB caused ATP depletion and contributed to cell death.Figure 3PB Inhibited NADH Dehydrogenase and ATP SynthesisThree biological replicates were used for each assay. Data are represented as mean ± SD.(A) Activity of membrane-bound NADH dehydrogenase after treatment of different concentrations of PB (20, 30, 40, 50, 60, 70 μg/mL). The absorbance level of NADH in the treatments of PB (0, 20, 30, 40, 50 μg/mL) was significantly different.(B) *In vivo* ATP levels of *B. subtilis* after treatment of different concentrations of PB (20, 30, 40, 50 μg/mL). The concentration of ATP in each sample was significantly different.(C) Growth curve of *B. subtilis* after treatment of PB and PB plus DCCD.(D) *In vivo* ATP levels of *B. subtilis* after treatment of PB and PB plus DCCD. \*p \< 0.05, \*\*p \< 0.01 by one-way ANOVA t test.

Glucose Maintained the Intracellular ATP Level in PB-Treated *B. subtilis* {#sec2.3}
--------------------------------------------------------------------------

Glucose is a key carbon source that supplies energy for bacterial growth ([@bib19]). This could keep the intracellular ATP level in PB-treated bacteria. To test this, the intracellular ATP levels were analyzed in the presence of PB, PB plus glucose, or glucose. As shown in [Figure 4](#fig4){ref-type="fig"}, ATP levels in PB-treated bacteria were much lower than that in the control. However, this was reverted by glucose, which increased the ATP level in the PB-treated bacteria to about 2-fold compared with control ([Figure 4](#fig4){ref-type="fig"}). It was noted that the ATP level in the PB plus glucose treatment was much lower than in the glucose only treatment, indicating that PB still inhibited ATP synthesis even in the presence of glucose.Figure 4Determination of Intracellular ATP Levels of *B. subtilis* with No Treatment and Treatment of PB, Glucose (Glc), and PB Plus GlcData are represented as mean ± SD. The ATP concentrations of the samples with no treatment and treatment of PB were significantly different (\*p \< 0.05).

In bacteria, glucose can generate ATP via glycolysis or the electron transport chain (ETC). To investigate if glucose enhanced ATP synthesis via ETC after PB treatment, we examined the PMF of the *B. subtilis* treated with PB or PB plus glucose. As shown in [Figure 5](#fig5){ref-type="fig"}A, the PMF of PB-treated bacteria was increased to some degree by glucose, but that was still lower than the PMF of the untreated bacteria. Fructose that enabled drug resistance had no effect on the PMF in PB-treated bacteria ([Figure 5](#fig5){ref-type="fig"}A). As glucose did not restore the PMF to the control level, we suggested that glucose might stimulate glycolysis to generate ATP in the presence of PB. To support this, we determined the intracellular metabolites (glucose, pyruvate, and acetate) of the glycolytic pathway to analyze glycolytic activity. As shown in [Figures 5](#fig5){ref-type="fig"}B--5D, the intracellular levels of these metabolites were significantly lower in the PB-treated *B. subtilis* than in the untreated ones, indicating that PB led to carbon source depletion and low glycolytic activity. However, the intracellular concentrations of glucose, pyruvate, and acetate were greatly increased in the PB treatment plus glucose, suggesting that glucose reverses carbon starvation and low glycolysis in the PB-treated bacteria. In the presence of PB, *B. subtilis* would uptake more glucose and increase the glycolytic pathway flux. These results showed that glucose induced bacterial resistance to PB by increasing intracellular ATP level via enhancement of glycolysis.Figure 5Analysis of PMF and Glycolysis MetabolitesThree biological replicates were used for each assay. Data are represented as mean ± SD.(A) PMF of *B. subtilis* with no treatment and treatment of PB plus no metabolite (PB), glucose (PB + Glc), arabinose (PB + Ara), glycerol (PB + Gly), and fructose (PB + Fru). The PMF of the samples with no treatment and treatment of PB were significantly different.(B) Intracellular glucose levels of *B. subtilis* with no treatment and treatment of PB, glucose (Glc), and PB plus glucose (PB + Glc). The glucose concentrations of the samples with no treatment and treatment of PB were significantly different.(C) Intracellular levels of pyruvate (Pyr) of *B. subtilis* with no treatment and treatment of PB, glucose (Glc), and PB plus glucose (PB + Glc). The pyruvate concentrations of the samples with no treatment and treatment of PB were significantly different.(D) Intracellular levels of acetate of *B. subtilis* with no treatment and treatment of PB, glucose (Glc), and PB plus glucose (PB + Glc). The acetate concentrations of the samples with no treatment and treatment of PB were significantly different. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001 by one-way ANOVA t test.

Glycolysis Is the Key Pathway that Enables PB Resistance in *B. subtilis* {#sec2.4}
-------------------------------------------------------------------------

To confirm that glycolysis enables PB resistance, the bacteria were treated with cysteine, an inhibitor of pyruvate kinase, to inhibit glycolysis flux ([@bib10]). As shown in [Figure 6](#fig6){ref-type="fig"}A, in the presence of cysteine, glucose could not induce resistance to PB in *B. subtilis*. We also tested the effect of the tricarboxylic acid (TCA) cycle on glucose-enabled drug resistance by treating *B. subtilis* with a high concentration of malonic acid (20 mM), an inhibitor of succinate dehydrogenase, to inhibit TCA flux ([@bib12]) ([Figure 6](#fig6){ref-type="fig"}C). Malonic acid did not eliminate glucose-enabled drug resistance, but the live percentage of the PB plus glucose plus malonic acid treatment was slower than the PB plus glucose treatment. These observations demonstrated that glycolysis was essential in glucose-enabled drug resistance, but the TCA cycle was not essential. Glucose catabolism could generate NADH, which is oxidized by ETC, contributes to PMF, and activates F0-F1 ATP synthase to generate ATP. Next, we investigated the effect of F0-F1 ATP synthase on glucose-enabled resistance by treating *B. subtilis* with DCCD, an inhibitor of F0-F1 ATP synthase ([@bib18]). With a DCCD supplement, we found that PB resistance could be eliminated by 2 mM DCCD. This result indicated that F0-F1 ATP synthase might also contribute to glucose-enabled drug resistance ([Figure 6](#fig6){ref-type="fig"}B).Figure 6Effect of Inhibitors on Glucose-Induced Drug ResistanceData are represented as Mean ± SD.(A) Live percentage of *B. subtilis* after no treatment (Control) and treatment of Glc, PB, PB plus glucose (PB + Glc), PB plus cysteine (PB + Cys), glucose plus cysteine (Glc + Cys), and PB plus glucose plus cysteine (PB + Glc + Cys).(B) Live percentage of *B. subtilis* after no treatment (Control) and treatment of Glc, PB, PB plus glucose (PB + Glc), PB plus DCCD (PB + DCCD), glucose plus DCCD (Glc + DCCD), and PB plus glucose plus DCCD (PB + Glc + DCCD).(C) Live percentage of *B. subtilis* after no treatment (Control) and treatment of Glc, PB, PB plus glucose (PB + Glc), PB plus malonic acid (PB + Mal), glucose plus malonic acid (Glc + Mal), and PB plus glucose plus malonic acid (PB + Glc + Mal).

Glucose Also Induced Bacterial Resistance to CLPs in *Staphylococcus aureus* {#sec2.5}
----------------------------------------------------------------------------

After showing that glucose induces resistance to CLPs in *B. subtilis*, we investigated if the phenomenon is applicable to *S. aureus*. As *S. aureus* is not sensitive to PB, we treated *S. aureus* with DAP (5 μg/mL). The results showed that DAP also resulted in serious ATP depletion leading to cell death in *S. aureus* ([Figures 7](#fig7){ref-type="fig"}A and 7B). With the addition of glucose, the ATP level was maintained and the killing activity of DAP was inhibited ([Figures 7](#fig7){ref-type="fig"}A and 7B). Moreover, we observed that glucose-induced drug resistance to CLPs in *S. aureus* was eliminated by cysteine ([Figure 7](#fig7){ref-type="fig"}A). Collectively, these observations demonstrated that glucose induces bacterial resistance to CLPs in *S. aureus* through the same mechanism as it does in *B. subtilis*.Figure 7Glucose Induced *S. aureus*\' Resistance to CLPsData are represented as mean ± SD.(A) Live percentage of *S. aureus* after no treatment (Control) and treatment of DAP, Glc, DAP plus glucose (DAP + Glc), DAP plus cysteine (DAP + Cys), glucose plus cysteine (Glc + Cys), and DAP plus glucose plus cysteine (DAP + Glc + Cys).(B) *In vivo* ATP levels of *S. aureus* after no treatment and treatment of DAP, glucose (Glc), and DAP plus glucose (DAP + Glc).

Discussion {#sec3}
==========

Previous knowledge about the mechanism of CLPs\' resistance in bacteria was restricted to cell surface modifications. However, we found that glucose could enable bacterial resistance to CLPs. To understand how glucose enables bacterial resistance to CLPs, we re-investigated CLPs\' action using PB as a model CLP. The CLPs\' mechanism was supposed to destroy lipid bilayer membrane integrity and cause dissipation of membrane potential ([@bib20]). However, several studies showed that the destruction of membrane integrity was not the sole killing mechanism in the action of CLPs ([@bib2], [@bib9], [@bib16], [@bib22], [@bib24]). That is because cellular processes such as cell division, cell wall component synthesis, and energetics are affected by membrane integrity ([@bib2], [@bib20]). In a recent study by Mogi et al., PB was found to be a potent inhibitor of membrane-bound NDH from *M. smegmatis*, indicating that PB might disturb the energetic status ([@bib16]). Here, we investigated the energy status of PB-treated bacteria. We found that PB would cause significant ATP depletion in *B. subtilis*. This contributed to its killing action, indicating that energetics is a PB target. Furthermore, we found that glucose could maintain the intracellular ATP level in PB-treated bacteria. We suggested that glucose enables bacterial PB resistance by maintaining the ATP level.

To scrutinize how glucose maintains the ATP level in PB-treated bacteria, we used proteomic analysis to investigate the metabolic status of bacteria after PB treatment. The results revealed that PB inhibited membrane-bound NDH in *B. subtilis* and caused down-regulation of respiration complexes, indicating that PB caused respiratory malfunction. PB treatment also caused PMF dissipation. These were the reasons why PB caused ATP depletion. PB treatment caused a significant response of carbon starvation. First, many proteins involved in transport and catabolism of alternative carbon sources were up-regulated ([@bib13], [@bib19]). Second, PB treatment also caused significant decrease in the levels of carbon metabolites *in vivo*, including glucose, pyruvate, and acetate. Thus, this could be explained by the fact that PB leads to low energy status and so more carbon sources were catabolized to maintain the energy status for survival. As a result, *in vivo* carbon metabolites were exhausted. However, this carbon starvation state was reverted by glucose. With a supplement of glucose, the bacteria could achieve enough carbon sources for survival. Owing to inhibition of respiration, the bacteria might maintain the energy status by enhancing glycolysis. To confirm this hypothesis, we compared the levels of the glycolytic metabolites, including glucose, pyruvate, and acetate in PB/glucose- and glucose-treated bacteria. The results showed that levels of the glucose, pyruvate, and acetate are much higher in PB/glucose-treated bacteria, demonstrating that glycolysis was enhanced by PB.

We also explored the role of the TCA cycle and F0-F1 ATP synthase in glucose-enabled drug resistance. The drug resistance could be eliminated by a high concentration of DCCD but not by malonic acid. This indicated that F0-F1 ATP synthase might partially contribute to PB resistance, but TCA does not. It seemed that glycolysis alone could not sustain survival of PB-treated bacteria in the glucose test concentration range. However, DCCD might have an additional effect, which causes dissipation of PMF in *B. subtilis* ([@bib4]). As glucose had no significant effect on restoration of the PMF, DCCD may cause a further dissipation of PMF, which may lead to cell lysis in *B. subtilis* ([@bib4]).

Inhibition of NDH will restrict NADH/NAD^+^ turnover leading to NAD^+^ limitation *in vivo* ([@bib8]). As NAD^+^ is the main oxidant in the cell, restoration of the NAD^+^ pool makes NADH turnover a top priority compared with ATP synthesis ([@bib25]). As seen in the proteomic results, NDH expression was 2-fold up-regulated in PB treatment but 1.3-fold up-regulated in PB plus glucose treatment. This indicated that glucose might revert the increase in NADH/NAD^+^. Here, we noted that NadA and NadB involved in NAD^+^ synthesis were significantly up-regulated (2.2-fold and 3.2-fold, respectively) with glucose supplement, but these two proteins were down-regulated (0.51-fold and 0.60-fold, respectively) with PB treatment. Thus, it was possible that glucose increased the NAD^+^ pool to revert the increase in NADH/NAD^+^. However, this hypothesis needs to be further confirmed.

This work demonstrated that bacterial sensitivity to CLPs is strongly related to energy metabolism. The relation between bacterial resistance to antibiotics and energy metabolism is also observed elsewhere ([@bib5], [@bib11], [@bib21]). Herein, we showed that CLPs could disturb ATP synthesis and cause cell death, but glucose can maintain the ATP level by enhancing glycolysis and enabling drug resistance ([Figure 8](#fig8){ref-type="fig"}). This study provides insight into the mode of action of CLPs and bacterial resistance mechanisms to CLPs.Figure 8The Mechanism Underlying Glucose-Induced Bacterial Resistance to CLPsCLPs inhibit aerobic respiration and cause PMF dissipation, leading to ATP depletion and contributing to cell death. Glucose maintains the ATP level by enhancing glycolysis and maintaining cell survival.

Limitations of the Study {#sec3.1}
------------------------

In this study, the molecular mechanism underlying ATP depletion induced by CLP antibiotics remains unclear.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.

Supplemental Information {#appsec2}
========================

Document S1. Transparent Methods and Figure S1Table S1. Significantly Differential (p \< 0.05) Expressing Proteins, Related to Figure 2Three tabs are included in this table. **Tab 1**: "Treatment of PB" includes differential expressing proteins in the treatment of PB only. **Tab 2**: "Treatment of PB plus Glucose" includes differential expressing proteins in the treatment of PB plus glucose. **Tab 3**: "Treatment of Glucose" includes differential expressing proteins in the treatment of glucose only.
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